Skip to main content
CERT
NASDAQ Life Sciences

Certara's Q1 Adjusted EPS Misses Estimates at $0.09, Despite Revenue Beat

feedReported by Reuters
Sentiment info
Negative
Importance info
8
Price
$6.22
Mkt Cap
$967.481M
52W Low
$5.19
52W High
$13.88
Market data snapshot near publication time

summarizeSummary

Certara reported Q1 adjusted EPS of $0.09, which missed the IBES estimate of $0.11. While the company's Q1 revenue of $106.9 million slightly exceeded the $106.1 million estimate, the miss on the bottom line is a significant concern for investors. This earnings report provides the first financial update since the full-year 2025 results, indicating a potential slowdown in profitability despite top-line growth. Professional traders would need to know about this immediately as an EPS miss often leads to negative stock price movement. Investors will be closely watching for management commentary on profitability trends and future guidance.

At the time of this announcement, CERT was trading at $6.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $967.5M. The 52-week trading range was $5.19 to $13.88. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.


show_chartPrice Chart

Share this article

Copied!

feed CERT - Latest Insights

CERT
May 11, 2026, 6:33 AM EDT
Filing Type: 10-Q
Importance Score:
8
CERT
May 11, 2026, 6:28 AM EDT
Filing Type: 8-K
Importance Score:
8
CERT
May 11, 2026, 6:25 AM EDT
Source: Reuters
Importance Score:
8
CERT
May 07, 2026, 8:02 AM EDT
Source: Reuters
Importance Score:
7
CERT
Apr 22, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
CERT
Apr 03, 2026, 6:00 AM EDT
Filing Type: DEF 14A
Importance Score:
7
CERT
Feb 26, 2026, 6:55 AM EST
Filing Type: 10-K
Importance Score:
8
CERT
Feb 26, 2026, 6:24 AM EST
Filing Type: 8-K
Importance Score:
8